Dendritic cell profiles in the inflamed colonic mucosa predict the responses to tumor necrosis factor alpha inhibitors in inflammatory bowel disease

Dendritic cell profiles in the inflamed colonic mucosa predict the responses to tumor necrosis factor alpha inhibitors in inflammatory bowel disease

Dendritic cells play crucial roles in the control of inflammation and immune tolerance in the gut. We aimed to investigate the effects of tumor necrosis factor alpha (TNFa) inhibitors on intestinal dendritic cells in patients with inflammatory bowel disease and the potential role of intestinal dendr...

Full description

Bibliographic Details
Main Authors:	Smrekar Natasa, Drobne David, Smid Lojze M., Ferkolj Ivan, Stabuc Borut, Ihan Alojz, Kopitar Andreja Natasa
Format:	Article
Language:	English
Published:	Sciendo 2018-11-01
Series:	Radiology and Oncology
Subjects:	inflammatory bowel disease dendritic cells tumor necrosis factor-alpha inhibitors colon cancer
Online Access:	https://doi.org/10.2478/raon-2018-0045

Similar Items

Dendritic cell activation and cytokine response in vaccine breakthrough TBE patients after in vitro stimulation with TBEV
by: Miša Marušić, et al.
Published: (2023-05-01)

Small bowel necrosis after esophagectomy
by: Longlong Shao, et al.
Published: (2023-03-01)

Unenhanced CT-based predictive model to identify small bowel necrosis in patients with mechanical small bowel obstruction
by: Xianwei Liu, et al.
Published: (2023-06-01)

Bowel necrosis in patient with severe case of COVID-19: a case report
by: Daniel Ardian Soeselo, et al.
Published: (2021-02-01)

Biosimilars to Antitumor Necrosis Factor Agents in Inflammatory Bowel Disease
by: Al Sulais E, et al.
Published: (2020-01-01)

Dynamic, Transient, and Robust Increase in the Innervation of the Inflamed Mucosa in Inflammatory Bowel Diseases
by: Miguel Gonzalez Acera, et al.
Published: (2021-08-01)

Small bowel transmural necrosis secondary to acute mesenteric ischemia and strangulated obstruction: CT findings of 49 patients
by: Watanya Jaidee, et al.
Published: (2023-07-01)

Biomarkers for prediction of CAR T therapy outcomes: current and future perspectives
by: Lucija Levstek, et al.
Published: (2024-03-01)

Two cases of small bowel necrosis due to intussusception secondary to abnormal proliferation of intestinal Peyer’s patches in infants after MMR vaccination
by: Junzhao Zhu, et al.
Published: (2024-02-01)

Clinical Features and Outcomes of Tuberculosis in Inflammatory Bowel Disease Patients Treated with Anti-tumor Necrosis Factor Therapy
by: Jihye Kim, et al.
Published: (2020-01-01)

Establishment of a risk prediction model for bowel necrosis in patients with incarcerated inguinal hernia
by: Jiajie Zhou, et al.
Published: (2024-02-01)

Remission Is Maintained after Switch from Dose-Optimised Intravenous Treatment to Subcutaneous Treatment with Vedolizumab in Inflammatory Bowel Disease
by: Špela Pintar, et al.
Published: (2024-02-01)

Dendritic Cell Vaccination in Metastatic Melanoma Turns “Non-T Cell Inflamed” Into “T-Cell Inflamed” Tumors
by: Jenny Bulgarelli, et al.
Published: (2019-10-01)

Clozapine-induced acute gastrointestinal necrosis: a case report
by: Mark T. Osterman, et al.
Published: (2017-09-01)

Neonatal Presentation of Unremitting Inflammatory Bowel Disease
by: Sara Ebrahimi, et al.
Published: (2018-05-01)

Association of tumor necrosis factor-α and -β gene polymorphisms in inflammatory bowel disease
by: Al-Meghaiseeb ES, et al.
Published: (2016-06-01)

Effects of Golimumab and Ustekinumab on Circulating Dendritic Cell Migratory Capacity in Inflammatory Bowel Disease
by: Irene Soleto, et al.
Published: (2023-10-01)

Microbial butyrate capacity is reduced in inflamed mucosa in patients with ulcerative colitis
by: Sushrut Jangi, et al.
Published: (2024-02-01)

Review: Local Tumor Necrosis Factor-α Inhibition in Inflammatory Bowel Disease
by: Bahez Gareb, et al.
Published: (2020-06-01)

Probiotic-Induced Tolerogenic Dendritic Cells: A Novel Therapy for Inflammatory Bowel Disease?
by: Shaghayegh Baradaran Ghavami, et al.
Published: (2021-07-01)

Poor prognostic factors of pharmacokinetic origin predict outcomes in inflammatory bowel disease patients treated with anti-tumor necrosis factor-α
by: Elizabeth A. Spencer, et al.
Published: (2024-01-01)

Corrigendum: Poor prognostic factors of pharmacokinetic origin predict outcomes in inflammatory bowel disease patients treated with anti-tumor necrosis factor-α
by: Elizabeth A. Spencer, et al.
Published: (2024-02-01)

The Use of Probiotic Therapy to Modulate the Gut Microbiota and Dendritic Cell Responses in Inflammatory Bowel Diseases
by: Pablo Alagón Fernández del Campo, et al.
Published: (2019-02-01)

A Narrative Review on Anti-Tumor Necrosis Factor α Therapies in Inflammatory Bowel Disease During Pregnancy: Immunoglobulin Placental Translocation and its Impact
by: Joana Roseira, et al.
Published: (2019-04-01)

Immunomodulation and Generation of Tolerogenic Dendritic Cells by Probiotic Bacteria in Patients with Inflammatory Bowel Disease
by: Shaghayegh Baradaran Ghavami, et al.
Published: (2020-08-01)

The Effect of Necrosis Inhibitor on Dextran Sulfate Sodium Induced Chronic Colitis Model in Mice
by: Dongwoo Kim, et al.
Published: (2023-01-01)

Plasmacytoid Dendritic Cells Are Largely Dispensable for the Pathogenesis of Experimental Inflammatory Bowel Disease
by: Catherine M. Sawai, et al.
Published: (2018-10-01)

Pregnancy outcome in women with inflammatory bowel disease treated with anti-tumor necrosis factor and/or thiopurine therapy: a multicenter study from Japan
by: Shunsuke Komoto, et al.
Published: (2016-04-01)

Dendritic cells: the yin and yang in disease progression
by: Carlos Jiménez-Cortegana, et al.
Published: (2024-01-01)

Construction and validation of a predictive model for the risk of bowel resection in adults with incarcerated groin hernia
by: Zheqi Zhou, et al.
Published: (2023-12-01)

Bacteroides thetaiotaomicron-derived outer membrane vesicles promote regulatory dendritic cell responses in health but not in inflammatory bowel disease
by: Lydia Durant, et al.
Published: (2020-06-01)

Influence of anti-tumor necrosis factor-alpha therapy to pregnant inflammatory bowel disease women and their children’s immunity
by: Ko Eun Lee, et al.
Published: (2019-04-01)

Ustekinumab Dosing Individualization in Crohn’s Disease Guided by a Population Pharmacokinetic–Pharmacodynamic Model
by: Jurij Aguiar Zdovc, et al.
Published: (2021-09-01)

Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 2: management
by: Dong Il Park, et al.
Published: (2018-01-01)

Tumor necrosis factor alpha and lipopolysaccharides synergistic effects on T-cell immunoglobulin and mucin domain 3 regulation in dendritic cells
by: Alia Aldahlawi, et al.
Published: (2022-08-01)

Skin gangrene as an extraintestinal manifestation of inflammatory bowel disease
by: Yumi Cristina Komatsu, et al.
Published: (2014-12-01)

Anti-tumor necrosis factor-α therapy may not be safe during pregnancy in women with inflammatory bowel disease: an updated meta-analysis and systematic review
by: Wei Huang, et al.
Published: (2024-04-01)

Risk and characteristics of tuberculosis after anti-tumor necrosis factor therapy for inflammatory bowel disease: a hospital-based cohort study from Korea
by: Jae Yong Lee, et al.
Published: (2021-10-01)

INFLIXIMAB AND TUMOUR NECROSIS FACTOR ALPHA MEASUREMENT ON INTESTINAL MUCOSA: A NEW TOOL FOR THE CLINIC?
by: Silvia Pecere, et al.
Published: (2016-12-01)

Severe ischemic bowel necrosis caused by terlipressin during treatment of hepatorenal syndrome
by: Hae Rim Kim, et al.
Published: (2013-12-01)